Litigation Details for Vanda Pharmaceuticals Inc. v. Teva Pharmaceuticals USA, Inc. (Fed. Cir. 2022)
✉ Email this page to a colleague
Vanda Pharmaceuticals Inc. v. Teva Pharmaceuticals USA, Inc. (Fed. Cir. 2022)
Docket | ⤷ Sign Up | Date Filed | 2022-12-15 |
Court | Court of Appeals for the Federal Circuit | Date Terminated | 2023-05-10 |
Cause | Assigned To | ||
Jury Demand | Referred To | ||
Patents | 10,149,829; 10,376,487; 9,730,910; RE46,604 | ||
Link to Docket | External link to docket |
Small Molecule Drugs cited in Vanda Pharmaceuticals Inc. v. Teva Pharmaceuticals USA, Inc.
Details for Vanda Pharmaceuticals Inc. v. Teva Pharmaceuticals USA, Inc. (Fed. Cir. 2022)
Date Filed | Document No. | Description | Snippet | Link To Document |
---|---|---|---|---|
0000-00-00 | External link to document | |||
2023-06-20 | 57 | Vanda-owned patents, U.S. Patent No. RE46,604 (the RE604 patent); U.S. Patent No. 10,149,829 (the ’829 …829 patent); U.S. Patent No. 9,730,910 (the ’910 patent); and U.S. Patent No. 10,376,487 (the ’487 patent…claim 3 of the RE604 patent; claim 14 of the ’829 patent; claim 4 of the ’910 patent; and claim 5 of the…foreclosing patentability. In finding obvious an asserted claim of the RE604 patent covering a …the ’487 patent. Teva and Apotex stipulated to infringement of claim 5 of the ’487 patent, denied infringement | External link to document | |
>Date Filed | >Document No. | >Description | >Snippet | >Link To Document |